Tirasemtiv
- Generic Name
- Tirasemtiv
- Drug Type
- Small Molecule
- Chemical Formula
- C12H14N4O
- CAS Number
- 1005491-05-3
- Unique Ingredient Identifier
- G8WSM7R635
- Background
Tirasemtiv has been used in trials studying the treatment of Myasthenia Gravis, Intermittent Claudication, and Amyotrophic Lateral Sclerosis.
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 280
- Registration Number
- NCT02936635
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Stanford Hospital and Clinics, Stanford, California, United States
🇺🇸The Emory Clinic, Atlanta, Georgia, United States
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: Placebo tablets
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 744
- Registration Number
- NCT02496767
- Locations
- 🇺🇸
West Virginia University Department of Neurology, Morgantown, West Virginia, United States
🇨🇦CHU de Quebec - Universite Laval Hopital de l'Enfant-Jesus, Quebec, Canada
🇺🇸Georgia Regents University, Augusta, Georgia, United States
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 711
- Registration Number
- NCT01709149
- Locations
- 🇺🇸
Texas Neurology, Dallas, Texas, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Drexel Neurology, Philadelphia, Pennsylvania, United States
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- First Posted Date
- 2011-12-07
- Last Posted Date
- 2019-05-03
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 27
- Registration Number
- NCT01486849
- Locations
- 🇺🇸
University of California at Irvine, ALS and Neuromuscular Center, Orange, California, United States
🇺🇸Coordinated Clinical Research, La Jolla, California, United States
🇺🇸Massachusetts General Hospital, Neurology Clinical Trials Unit, Charlestown, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.